Skip to main content
Teva Pharmaceutical Industries Ltd. logo

Teva Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · TEVA ISIN · US8816242098 LEI · 549300BAFGM4RC74ZJ94 TA Manufacturing
Open in API
Filings indexed 6,088 across all filing types
Latest filing 2026-06-01 Director's Dealing
Country IL Israel
Listing TA TEVA

About Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that develops, produces, and markets a broad portfolio of medicines. The company's business is centered on two main segments: generic medicines and innovative specialty treatments. As one of the world's largest manufacturers of generic drugs, Teva provides a wide range of affordable products across numerous therapeutic areas. Its specialty and biopharmaceutical research focuses on developing novel treatments, with a significant emphasis on central nervous system (CNS) disorders, including therapies for schizophrenia, tardive dyskinesia, and bipolar disorder. The company's portfolio also includes complex generics, biosimilars, and active pharmaceutical ingredients (APIs), while leveraging advanced technologies to enhance drug development and manufacturing.

Recent filings

Filing Released Lang Actions
Immediate Report
Director's Dealing Classification · 97% confidence The document is an SEC Form 4 reporting non‐derivative and derivative securities transactions by a director/officer (insider trades). This aligns exactly with the 'Director's Dealing' category (insider share transactions).
2026-06-01 English
Immediate Report
Director's Dealing Classification · 89% confidence The document is an Israeli ‘Immediate Report’ under Regulation 4 concerning a change in holdings by an officer and attaches a Form 4 insider transaction report. This is a personal share transaction by a company director/executive (insider dealing), matching the Director’s Dealing category.
2026-06-01 English
Immediate Report
Director's Dealing Classification · 94% confidence The document is a U.S. SEC Form 4 "Statement of Changes in Beneficial Ownership of Securities," which reports insider transactions by a company director/officer. This falls squarely under Director’s Dealing filings (insider share transactions).
2026-06-01 English
Immediate Report
Director's Dealing Classification · 90% confidence The document is an immediate report filed under the Israel Securities Authority and Tel Aviv Stock Exchange regulations. It is titled “Immediate Report – Change in Holdings of Officeholder” and references a Form 4 PDF detailing share transactions by a person in office. This corresponds to insider share transactions by company directors/executives. Therefore, it matches the Director’s Dealing category.
2026-06-01 English
Immediate Report
Director's Dealing Classification · 95% confidence The document is clearly a Form 4 reporting insider transactions by a company director, including the number of restricted share units acquired and beneficial ownership details, which matches the insider dealing disclosure requirements under Section 16. This falls under Director’s Dealing filings.
2026-06-01 English
Immediate Report
Director's Dealing Classification · 98% confidence The document is an Immediate Report under Israeli Securities Regulations 5761-2000 detailing a change in holdings by a corporate officer (“Form_4_Perry_Nisen”). This is an insider transaction report by a director/executive. Thus it matches the Director’s Dealing category.
2026-06-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.